Reduced-Intensity Conditioning in Allogeneic Stem Cell Transplantation for Hematological Malignancies: A Historical Perspective

被引:6
作者
Cremer, Birgit [1 ]
Sandmaier, Brenda M. [2 ,3 ]
Bethge, Wolfgang [4 ]
Lange, Thoralf [5 ]
Goede, Valentin [1 ]
Holtick, Udo [1 ]
Hallek, Michael [1 ]
Huebel, Kai [1 ]
机构
[1] Univ Cologne, Innere Med Klin 1, Cologne, Germany
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Univ Tubingen, Med Klin 2, D-72074 Tubingen, Germany
[5] Univ Leipzig, Dept Hematol, Leipzig, Germany
来源
ONKOLOGIE | 2011年 / 34卷 / 12期
关键词
Reduced-intensity conditioning; Hematology; Allogeneic stem cell transplantation; CHRONIC LYMPHOCYTIC-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; RELAPSED FOLLICULAR LYMPHOMA; MINIMAL RESIDUAL DISEASE; VERSUS-HOST-DISEASE; MULTIPLE-MYELOMA; HODGKINS-LYMPHOMA; PREPARATIVE REGIMENS; SALVAGE TREATMENT; GRAFT;
D O I
10.1159/000334542
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Allogeneic hematopoietic stem cell transplantation represents a curative treatment approach for a large range of hematologic malignancies. Traditionally, high-dose radiochemotherapy as preparative regimen has been thought to be necessary for successful allogeneic stem cell transplantation. However, high-dose conditioning often results in considerable medullary and extramedullary toxicity, contributing to high rates of treatment-related mortality. This limits the use of this procedure to patients below 60 years of age without significant comorbidities. Since the peak incidence of most hematological malignancies is beyond the 5th decade of life, the majority of patients are not eligible for high-dose treatment. During the last 15 years, several dose-reduced or even non-myeloablative conditioning regimens have been developed, offering a curative treatment option for these patients. This review summarizes the history of reduced-intensity conditioning (RIC) transplantations, depicts the differences among regimens, highlights significant patient factors, and describes the impact on selected hematological malignancies.
引用
收藏
页码:710 / 715
页数:6
相关论文
共 47 条
[1]   Long-term results of blood and marrow transplantation for Hodgkin's lymphoma [J].
Akpek, G ;
Ambinder, RF ;
Piantadosi, S ;
Abrams, RA ;
Brodsky, RA ;
Vogelsang, GB ;
Zahurak, ML ;
Fuller, D ;
Miller, CB ;
Noga, SJ ;
Fuchs, E ;
Flinn, IW ;
O'Donnell, P ;
Seifter, EJ ;
Mann, RB ;
Jones, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (23) :4314-4321
[2]  
Alousi Amin, 2007, Clin Adv Hematol Oncol, V5, P560
[3]   Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma:: Results of a Spanish prospective cooperative protocol [J].
Alvarez, I ;
Sureda, A ;
Caballero, MD ;
Urbano-Ispizzua, A ;
Ribera, JM ;
Canales, M ;
García-Conde, J ;
Sanz, G ;
Arranz, R ;
Bernal, MT ;
de la Serna, J ;
Díez, JL ;
Moraleda, JM ;
Rubió-Félix, D ;
Xicoy, B ;
Martínez, C ;
Mateos, MV ;
Sierra, J .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) :172-183
[4]   Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age [J].
Alyea, EP ;
Kim, HT ;
Ho, V ;
Cutler, C ;
Gribben, J ;
DeAngelo, DJ ;
Lee, SJ ;
Windawi, S ;
Ritz, J ;
Stone, RM ;
Antin, JH ;
Soiffer, RJ .
BLOOD, 2005, 105 (04) :1810-1814
[5]   Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen [J].
Anderlini, P ;
Saliba, R ;
Acholonu, S ;
Okoroji, GJ ;
Donato, M ;
Giralt, S ;
Andersson, B ;
Ueno, NT ;
Khouri, I ;
De Lima, M ;
Hosing, C ;
Cohen, A ;
Ippoliti, C ;
Romaguera, J ;
Rodriguez, MA ;
Pro, B ;
Fayad, L ;
Goy, A ;
Younes, A ;
Champlin, RE .
BONE MARROW TRANSPLANTATION, 2005, 35 (10) :943-951
[6]   Fludarabine-meiphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience [J].
Anderlini, Paolo ;
Saliba, Rima ;
Acholonu, Sandra ;
Giralt, Sergio A. ;
Andersson, Borje ;
Ueno, Naoto T. ;
Hosing, Chitra ;
Khouri, Issa F. ;
Couriel, Daniel ;
de Lima, Marcos ;
Qazilbash, Muzaffar H. ;
Pro, Barbara ;
Romaguera, Jorge ;
Fayad, Luis ;
Hagemeister, Frederick ;
Younes, Anas ;
Munsell, Mark F. ;
Champlin, Richard E. .
HAEMATOLOGICA, 2008, 93 (02) :257-264
[7]   Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: Where do we stand? [J].
Anderlini, Paolo ;
Champlin, Richard E. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (06) :599-602
[8]   ALLOGENEIC, SYNGENEIC, AND AUTOLOGOUS MARROW TRANSPLANTATION FOR HODGKINS-DISEASE - THE 21-YEAR SEATTLE EXPERIENCE [J].
ANDERSON, JE ;
LITZOW, MR ;
APPELBAUM, FR ;
SCHOCH, G ;
FISHER, LD ;
BUCKNER, CD ;
PETERSEN, FB ;
CRAWFORD, SW ;
PRESS, OW ;
SANDERS, JE ;
BENSINGER, WI ;
MARTIN, PJ ;
STORB, R ;
SULLIVAN, KM ;
HANSEN, JA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2342-2350
[9]  
Bacigalupo A, 2004, BONE MARROW TRANSPL, V33, pS29, DOI 10.1038/sj.bmt.1704416
[10]   A comparison of allografting with autografting for newly diagnosed myeloma [J].
Bruno, Benedetto ;
Rotta, Marcello ;
Patriarca, Francesca ;
Mordini, Nicola ;
Allione, Bernardino ;
Carnevale-Schianca, Fabrizio ;
Giaccone, Luisa ;
Sorasio, Roberto ;
Omede, Paola ;
Baldi, Ileana ;
Bringhen, Sara ;
Massaia, Massimo ;
Aglietta, Massimo ;
Levis, Alessandro ;
Gallamini, Andrea ;
Fanin, Renato ;
Palumbo, Antonio ;
Storb, Rainer ;
Ciccone, Giovannino ;
Boccadoro, Mario .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (11) :1110-1120